AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson’s disease meets primary endpoint
January 04, 2024 02:30 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany/Research Triangle Park, North Carolina, USA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1005 (AAV2-GDNF), an investigational gene therapy for the...